This Washington Black Man Would Be Dead Without AI, Here's What We Know
There was thought to be no hope for Joseph Coates nearly a year ago. However, after his girlfriend begged for help from a Philadelphia doctor, the young Black man who had so much more life to live received help from the unlikeliest of places.
According to the New York Times, Coates had been suffering from POEMS syndrome, a blood disorder that hurts your nerves and other parts of your body. In the case of the 37-year-old Coates, his hands and feet became numb and he had an enlarged heart and kidneys that were failing.
Thinking there was nowhere else to turn, Tara Theobald, Coates' girlfriend, reached out to Dr. David C. Fajgenbaum, a professor at the University of Pennsylvania Perelman School of Medicine.
But, Dr. Fajgenbaum didn't use his own brain to discover a way to treat Coates' rare blood disorder, he used artificial intelligence.
More from the New York Times:
In labs around the world, scientists are using A.I. to search among existing medicines for treatments that work for rare diseases. Drug repurposing, as it's called, is not new, but the use of machine learning is speeding up the process — and could expand the treatment possibilities for people with rare diseases and few options.
Thanks to versions of the technology developed by Dr. Fajgenbaum's team at the University of Pennsylvania and elsewhere, drugs are being quickly repurposed for conditions including rare and aggressive cancers, fatal inflammatory disorders and complex neurological conditions.
Dr. Fajgenbaum used AI to come up with a unique solution using steroids, chemotherapy, and other untested treatments to help Coates' disorder. Although there were initial worries that the treatment might worsen his life, it did the opposite and made him recover faster than anyone would've hoped.
It was so successful that four months later he was approved for the stem cell treatment that would improve his condition and currently, the 37-year-old is in remission.
For the latest news, Facebook, Twitter and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Novartis announces data from new subgroup analysis of Phase III NATALEE trial
Novartis (NVS) is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali plus endocrine therapy in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer, EBC, at high risk of recurrence across age and menopausal status. The data will be presented at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. Results at median follow-up of 44.2 months show that patients receiving Kisqali continued to see consistent reductions in risk of recurrence across all efficacy measures, regardless of age and menopausal status. In this one-year post-treatment analysis, pre-menopausal and younger patients, who often present with more aggressive disease characteristics, experienced greater reductions in risk of recurrence and fewer treatment discontinuations due to adverse events than post-menopausal patients. Results include: 33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer patients receiving Kisqali in 1-year post-treatment analysis; Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients; Separate real-world analysis presented at ASCO demonstrates differences in treatment outcomes that underscore critical need to improve care for Black patients with EBC. Confident Investing Starts Here:
Yahoo
7 hours ago
- Yahoo
Fox News Host Slams Musk for Dodging Drug Use Question
Fox News host Howard Kurtz has called out Elon Musk for deflecting questions about his alleged drug use while serving in the White House. The New York Times published a bombshell report this week on Musk's alleged drug habits when he was President Donald Trump's senior adviser at the Department of Government Efficiency (DOGE), which reportedly included taking magic mushrooms, ecstasy, Adderall, and enough ketamine to cause bladder issues. Musk was asked about the Times report during a press briefing at the Oval Office marking the end of his tenure at DOGE on Friday. 'Wait, wait, The New York Times, is that the same publication that got a Pulitzer Prize for false reporting on Russiagate? Is it the same organization?' Musk replied before saying, 'Let's move on.' Kurtz pointed out on Media Buzz Sunday that Musk 'decided to talk about something from five years ago involving the Pulitzers because he knew that he did not want to answer that question. That's my take.' 'That's called deflection,' he added. But Fox News contributor Toni Lahren said that she wasn't sure if the Times 'produced any real evidence of a so-called drug problem,' claiming that the left was simply 'looking for some kind of scandal.' 'The left loved Elon Musk even if he was a billionaire that did mushrooms on the side and maybe a little ketamine. They didn't have a single problem with it. They loved the Teslas. They loved Elon. They loved space flight. They loved all of it,' she said. 'And then he came out as a Trump supporter and now you've got headline news—with everything going on in the country, in the world—about Elon Musk allegedly, maybe doing some mushrooms, maybe a little adderall,' Lahren added. 'Again, please spare me.' She said that even if Musk was actually taking drugs, his potential 'recreational drug use' didn't impact 'everyday Americans.' 'I know that they're looking for some kind of scandal there, but I think it's a real nothing burger and I don't think many people quite frankly, care what Elon Musk does in his personal private time,' she said. Musk has previously publicly acknowledged using ketamine. In an interview with former CNN host Don Lemon last year, he admitted to taking a 'small amount' of ketamine to treat depression. A clip has also recently resurfaced of Musk at Trump's Bedminster golf club in New Jersey in March balancing spoons with Shivon Zilis, one of the mothers of his children. Social media users have accused him of 'tripping on ketamine' in the clip. 'I'm not on ketamine ffs,' Musk wrote in response to the clip.
Yahoo
7 hours ago
- Yahoo
Even Fox News isn't impressed with Musk dodging question over alleged drug use
A Fox News host called out Elon Musk's response to the New York Times report alleging drug use while the billionaire was working as Trump's senior adviser at the Department of Government Efficiency. The Times report alleged that Musk was frequently using magic mushrooms, ecstasy, Adderall, and ketamine in amounts that caused him bladder issues. When asked about the report during an Oval Office press briefing on Friday, Musk questioned the newspaper's credibility. 'Wait, wait, The New York Times, is that the same publication that got a Pulitzer Prize for false reporting on Russiagate? Is it the same organization?' Musk replied. 'Let's move on.' On Sunday, Fox News anchor Howard Kurtz called out Musk for refusing to answer the question directly, saying he 'decided to talk about something from five years ago involving the Pulitzers because he knew that he did not want to answer that question. That's my take.' "That's called deflection," Kurtz said. Musk has previously admitted to using a "small amount" of ketamine to treat depression. He made the admission in an interview with former CNN host Don Lemon in 2024. Critics of Musk on social media — including his own platform, X — have been quick to accuse him of being under the influence of drugs, generally in response to videos of him doing odd things. In a recent video in which Musk was recorded stacking spoons at a dinner, one X user accused him of "tripping on ketamine" while visiting Trump's Bedminster golf club. Musk replied to the accusation by saying, "I'm not on ketamine ffs." Another video of Musk's recent appearance in the Oval Office, which shows him lolling his head and rolling his eyes while Trump was speaking. His appearance — including a black eye he said he received while playing with his young son — was similarly lampooned on social media. Musk's latest visit to the Oval Office was something of a send off; his predetermined time serving as Trump's senior adviser at DOGE has expired, and he appears to be returning to the private sector to focus on his businesses, though the president insists that the world's richest man will still be hanging around DC.
